Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 11, 2012, Pages 2014-2021

  Mattern, Michael R ^a   Wu, Jian ^a   Nicholson, Benjamin ^a  

^a Progenra Inc   (United States)

Author keywords

Anticancer drugs; Deubiquitylase; E3 ligase; Proteasome inhibitor; Ubiquitin

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; ANTINEOPLASTIC AGENT; B AP 15; BORTEZOMIB; CARFILZOMIB; CC 0651; CHLOROQUINE; CLIOQUINOL; DELANZOMIB; GDC 0152; IPSI 001; IXAZOMIB CITRATE; LIGASE INHIBITOR; NC 002; NSC 652287; OPROZOMIB; P 0050429; PR 047; PR 619; PROTEASOME INHIBITOR; PYR 41; RO 5045337; SALINOSPORAMIDE A; SERDEMETAN; UBIQUITIN; UBIQUITIN ACTIVATING ENZYME E1; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINYL SULFONE INHIBITOR4;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CARDIOTOXICITY; ENZYME ACTIVE SITE; ENZYME BINDING; FOOD AND DRUG ADMINISTRATION; HUMAN; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84866988499     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.05.005     Document Type: Article

References (44)

1. Nowis D., Maczewski M., Mackiewicz U., Kujawa M., Ratajska A., Wieckowski M.R., Wilczynski G.M., Malinowska M., Bil J., Salwa P., Bugajski M., Wojcik C., Sinski M., Abramczyk P., Winiarska M., Dabrowska-Iwanicka A., Duszynski J., Jakobisiak M., Golab J. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am. J. Pathol. 2010, 176:2658-2668.
2. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., Adams J., Esseltine D.L., Elliott P.J., Pien C.S., Guerciolini R., Anderson J.K., Depcik-Smith N.D., Bhagat R., Lehman M.J., Novick S.C., O'Connor O.A., Soignet S.L. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20:4420-4427.
3. Molineaux S.M. Molecular pathways: targeting proteasomal protein degradation in cancer. Clin. Cancer Res. 2012, 18:15-20.
4. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
5. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., Munshi N., Dang L., Castro A., Palombella V., Adams J., Anderson K.C. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 2002, 277:16639-16647.
6. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2003, 2:835-843.
7. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T.A., Schlossman R., Munshi N.C., Hideshima T., Anderson K.C. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380.
8. Oerlemans R., Franke N.E., Assaraf Y.G., Cloos J., vanZantwijk I., Berkers C.R., Scheffer G.L., Debipersad K., Vojtekova K., Lemos C., van der Heiden J.W., Yistra B., Peters G.J., Kaspers G.L., Dijkmans B.A.C., Scheper R.J., Jansen G. Molecular basis of bortezomib resistance: protease subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
9. Suzuki E., Demo S., Deu E., Keats J., Arastu-Kapur S., Bergsagel P.L., Bennett M.K., Kirk C.J. Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One 2011, 6:e27996.
10. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl. Cancer Inst. 2011, 103:1007-1017.
11. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., Sun C.M., Demo S.D., Bennett M.K., van Leeuwen F.W., Chanan-Khan A.A., Orlowski R.Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
12. Kuhn D.J., Hunsucker S.A., Chen Q., Voorhees P.M., Orlowski M., Orlowski R.Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113:4667-4676.
13. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., Nicholson B., Chao T.H., Neuteboom S.T., Richardson P., Palladino M.A., Anderson K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8:407-419.
14. Kisselev A.F., Garcia-Calvo M., Overkleeft H.S., Peterson E., Pennington M.W., Ploegh H.L., Thornberry N.A., Goldberg A.L. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. 2003, 278:35869-35877.
15. van Swieten P.F., Samuel E., Hernandez R.O., van den Nieuwendijk A.M., Leeuwenburgh M.A., van der Marel G.A., Kessler B.M., Overkleeft H.S., Kisselev A.F. A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg. Med. Chem. Lett. 2007, 17. (3402-3434-3405).
16. Mirabella A.C., Pletnev A.A., Downey S.L., Florea B.I., Shabaneh T.B., Britton M., Verdoes M., Filippov D.V., Overkleeft H.S., Kisselev A.F. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem. Biol. 2011, 18:608-618.
17. D'Arcy P., Brnjic S., Olofsson M.H., Fryknas M., Lindsten K., De Cesare M., Perego P., Sadeghi B., Hassan M., Larsson R., Linder S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 2011, 17:1636-1640.
18. Ciechanover A., Orian A., Schwartz A.L. The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications. J. Cell. Biochem. 2000, 77:40-51.
19. Chen J.J., Tsu C.A., Gavin J.A., Milhollen M.A., Bruzzese F.J., Mallender W.D., Sintchak M.D., Bump N.J., Yang X., Ma J., Loke H.-K., Xu Q., Li P., Bence N.F., Brownell J.E., Dick L.R. Mechanistic studies of subtrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues. J. Biol. Chem. 2011, 286:40867-40877.
20. Chen Q., Xie W., Kuhn D.J., Voorhees P.M., Lopez-Girona A., Mendy D., Corral L.G., Plantevin Krenitsky V., Xu W., Moutouh-de Parseval L., Webb D.R., Mercurio F., Nakayama K.I., Nakayama K., Orlowski R.Z. Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008, 111:4690-4699.
21. Yang Y., Kitagati J., Dai R.-M., Tsai Y.C., Lorick K.L., Ludwig R.L., Pierre S.A., Jensen J.P., Davydov I.V., Oberoi P., Li C.-C.H., Kenten J.H., Beutler J.A., Vousden K.H., Weissman A.M. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 2007, 67:9472-9481.
22. Ceccarelli D.F., Tang X., Pelletier B., Orlicky S., Xie W., Plantevin V., Neculai D., Chou Y.C., Ogunjimi A., Al-Hakim A., Varelas X., Koszela J., Wasney G.A., Vedadi M., Dhe-Paganon S., Cox S., Xu S., Lopez-Girona A., Mercurio F., Wrana J., Durocher D., Meloche S., Webb D.R., Tyers M., Sicheri F. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 2011, 145:1075-1087.
23. Yuan Y., Liao Y.-M., Hsueh C.-T., Mirshahidi H.R. Novel and targeted therapeutics: inhibitors of MDM2, ALK, and PARP. J. Hematol. Oncol. 2011, 4. (open access http://www.jhoonline.org/4/1/16).
24. Cohen P.T., M. Will the ubiquitin system furnish as many drug targets as protein kinases?. Cell 2010, 143:686-693.
25. Suzuki K., Matsubara H. Recent advances in p53 research and cancer treatment. J. Biomed. Biotechnol. 2011, 2011:978312.
26. Garber K. Missing the target: ubiquitin ligase drugs stall. J. Natl. Canc. Inst. 2005, 97:166-167.
27. Shi D., Grossman S.R. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol. Ther. 2010, 10:737-747.
28. Azmi A.S., Philip P.A., Beck F.W.J., Wang Z., Yang D., Sarkar F.H., Mohammad R.M. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene 2011, 30:117-126.
29. Mullally J.E., Moos P.J., Edes K., Fitzpatrick F.A. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J. Biol. Chem. 2001, 276:30366-30373.
30. Altun M., Kramer H.B., Willems L.I., McDermott J.L., Leach C.A., Goldenberg S.J., Kumar K.G., Konietzny R., Fischer R., Kogan E., Mackeen M.M., McGouran J., Khoronenkova S.V., Parsons J.L., Dianov G.L., Nicholson B., Kessler B.M. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 2011, 18:1401-1412.
31. Colland F., Formstecher E., Jacq X., Reverdy C., Planquette C., Conrath S., Trouplin V., Bianchi J., Aushev V.N., Camonis J., Calabrese A., Borg-Capra C., Sippl W., Collura V., Boissy G., Rain J.C., Guedat P., Delansorne R., Daviet L. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 2009, 8:2286-2295.
32. Reverdy C., Conrath S., Lopez R., Planquette C., Atmanene C., Collura V., Harpon J., Battaglia V., Vivat V., Sippl W., Colland F. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem. Biol. 2012, 19:467-477.
33. Mermerian A.H., Case A., Stein R.L., Cuny G.D. Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:3729-3732.
34. Cao P., Weinstock J., Kingsbury W.D., Leach C.A., Kizhakkethil George S.K., Nicholson B. Antineoplastic compounds, compositions and methods., PCT/US2010/029358 2009.
35. Kapuria V., Peterson L.F., Fang D., Bornmann W.G., Talpaz M., Donato N.J. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010, 70:9265-9276.
36. Ratia K., Pegan S., Takayama J., Sleeman K., Coughlin M., Baliji S., Chaudhuri R., Fu W., Prabhakar B.S., Johnson M.E., Baker S.C., Ghosh A.K., Mesecar A.D. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16119-16124.
37. Nicholson B., Marblestone J.G., Butt T.R., Mattern M.R. Deubiquitinating enzymes as novel anticancer targets. Future Oncol. 2007, 3:191-199.
38. Reyes-Turcu F.E., Ventii K.H., Wilkinson K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 2009, 78:363-397.
39. Lee M.J., Lee B.H., Hanna J., King R.W., Finley D. Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Mol. Cell. Proteomics 2011, 10. (R110 003871).
40. Larsen C.N., Price J.S., Wilkinson K.D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 1996, 35:6735-6744.
41. Everett R.D., Meredith M., Orr A., Cross A., Kathoria M., Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 1997, 16:1519-1530.
42. Cummins J.M., Rago C., Kohli M., Kinzler K.W., Lengauer C., Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004, 428. (1 p following 486).
43. Li M., Brooks C.L., Kon N., Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 2004, 13:879-886.
44. Rusnak D.W., Affleck K., Cockerill S.G., Stubberfield C., Harris R., Page M., Smith K.J., Guntrip S.B., Carter M.C., Shaw R.J., Jowett A., Stables J., Topley P., Wood E.R., Brignola P.S., Kadwell S.H., Reep B.R., Mullin R.J., Alligood K.J., Keith B.R., Crosby R.M., Murray D.M., Knight W.B., Gilmer T.M., Lackey K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001, 61:7196-7203.